|
| ID | Diagnostic criteria of CHD (ACS) | Diagnostic criteria of dyslipidemia | Types of CHD | Sample size (I/C) | Age (y, I/C) | Interventions group | Control group | Duration of treatment | Outcomes evaluation | Balance
report
of
baseline |
|
CCSPS 2005
[4] | Not specified | TC: 4.40–6.47 | MI | 2441/2429 | (Male: ;
female: )
/(male: ;
female: 6 | Xuezhikang 600 mg therapy (no detail) | Placebo + conventional therapy (no detail) | 4 year
in average | Serum lipid level (TC, TG, LDL-C, HDL-C), all-cause mortality, cardiovascular events, serum lipid level (TC, TG, HDL-C, LDL-C),
ADs | Yes |
|
|
Dai et al. 1999 [5] | WHO 1979 and Gao 1994 | Ministry of Health of the People’s Republic of China 1993 | Unstable angina | 33/25 | | Xuezhikang 600 mg, | Nitrate esters 10 mg BID + nifedipine GIFTS 30 mg QD/diltiazem 30 mg tid + metoprolol 12.5 mg BID + aspirin 50 mg QD | 8 weeks | Serum lipid level (TC, TG, HDL-C, LDL-C), ADs | Yes |
|
|
Gao and Liao 2003 [21] | Not specified | mmol/L,
LDL- mmol/L,
mmol/L | Stable Angina | 30/30 | 53–85, 67.5 in average | Xuezhikang 600 mg therapy (no detail) | Fluvastatin (Lescol see fluvastatin) 20 mg QD + conventional therapy (no detail) | 4 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C) | Unclear |
|
Guan 2010
[22] | Not specified | mmol/L;
; LDL-;
.
Two items of the above were included | Stable Angina | 72/64 | 49–76, 62 in
average | Xuezhikang 600 mg BID | Simvastatin 10 mg QN | 1 year | CHD mortality, ADs | Yes |
|
|
Huang et al. 2005 [23] | WHO 1979 | CADPS 1997 | OMI and UA | 45/63 | 44–72 | Xuezhikang 600 mg BID | Simvastatin 20 mg QN | 6 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C) | Yes |
|
|
Huang et al. 2009 [24] | WHO 1979 | CADPS 1997 | Unclear | | | Xuezhikang 600 mg, | Nitroglycerine 20 mg BIDIV + 10% KCL + insulinIV QD | 12 weeks | Serum lipid level (TC, TG, HDL-C, LDL-C) | Yes |
|
|
Jiang and Cai 2001 [25] | Not specified | CADPS 1997 | Unclear | | | Xuezhikang 600 mg therapy (as same as B) | Simvastatin 10 mg QN + conventional therapy (nitrate esters 10 mg tid, aspirin 100 mg QD or anticoagulation drugs or thrombolytic drug or hypoglycemic) | 8 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C), ADs | Yes |
|
|
Li et al. 2011 [26] | References [12, 13] | As same as Guan 2010 | Unclear | |
| Xuezhikang 600 mg BID | Lovastatin 40 mg QD (20 mg QD if the ALT or AST was 3 times higher than the normal) | 8 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C), ADs | Yes |
|
|
Lin et al. 2009 [27] | Chinese Society of cardiology 2000 | mmol/L
or LDL- mmol/L | Unstable angina | | 35–71, 55.4 in average | Xuezhikang 600 mg, | Simvastatin 60 mg QN + conventional therapy (nitrate esters, β adrenergic blocking agent, CCB, aspirin, low molecular heparin and et al. | 6 months | Serum lipid level (TC, LDL-C), CHD events | Yes |
|
|
Lou et al. 2008 [28] | Chinese society of cardiology 2000 | mmol/L
and mmol/L
and LDL- | Unstable angina | | | Xuezhikang 600 mg therapy (as same as B) | Simvastatin 20 mg QD + conventional therapy (anticoagulation drugs, nitrate esters, β adrenergic blocking agent, ACEI, CCB and et al.) | 6 months | Serum lipid level (TC, TG, LDL-C, HDL-C), Cardiovascular events, ADs | Unclear |
|
|
Ma and Teng 2005 [29] | WHO 1979 | CADPS 1997 | Unclear | |
| Xuezhikang 600 mg | Conventional therapy (nitrate esters, adrenergic blocking agent, ACEI, CCB and et al.) | 8 weeks | Serum lipid level (TC, TG) | Yes |
|
|
Qi et al. 2001 [30] | WHO 1979 | mmol/L | Unclear | | | Xuezhikang 600 mg, BID (600 mg TID if the lipid level was still higher than the treatment goal) + control | Conventional therapy (nitrate esters, adrenergic blocking agent, ACEI, CCB, and et al.) | 12 weeks | Serum lipid level (TC, TG), ADs | Unclear |
|
Shang 2007
[31] | WHO 1979 | CADPS 1997 | Stable Angina | | | Xuezhikang 1200 mg therapy (as same as control group) | Atorvastatin 10 mg QN + conventional therapy (aspirin, nitrate esters, β adrenergic blocking agent, ACEI, and et al.) | 2 months | Serum lipid level (TC, TG, LDL-C, HDL-C) | Yes |
|
|
Wang and Xiao 2000 [32] | WHO 1979 | CADPS 1997 | MI, UA, CHD with no symptoms | | 49–76, 62 in average | Xuezhikang 600 mg 50 mg QD | Inositol niacinate 400 mg TID + aspirin 50 mg QD | 1 year | Serum lipid level (TC, TG, LDL-C, HDL-C), cardiovascular evnets, ADs | Yes |
|
Wang et al.
2004 [6] | ACC/AHH 2000 | CADPS 1997 | ACS | |
| Xuezhikang 600 mg | Conventional therapy (aspirin, nitrate esters, β adrenergic blocking agent, ACEI, and et al.) | 12 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C), ADs | Yes |
|
| Xu 2005 [39] | Chinese Society of cardiology 2000 | Not specified | UA | | Unclear | Xuezhikang 600 mg group (1) | (1) Conventional therapy (isosorbide dinitrate 10 mg tid, betaloc 25–50 mg BID/TID, aspirin 50–150 mg QD, low molecular heparin 0.4–0.6 mL Q12H or diltiazem 30 mgtid/qid, or plendil 5 mg QD/BID or captopril 12.5–25 mg TID or nitroglycerine)
(2) Conventional therapy (as same as (1)) and atorvastatin 20 mg Qn | 1 month | Serum lipid level (TC, TG, LDL-C, HDL-C) | Yes |
|
| Yan 2006 [34] | Chinese Society of cardiology 2000 | LDL-C: 1.84–4.12 mmol/L | UA | | | Xuezhikang 600 mg | magnesium polarizing liquorIV + heparinIH + Aspirin, Nitrate esters, β adrenergic blocking agent CCB and et al. | 8 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C), ADs | Unclear |
|
Yan and Li
2007 [33] | WHO 1979 | CADPS 1997 | Unclear | |
| Xuezhikang 600 mg, | Nitroglycerine 20 mg BID.iv + 10% KCL + insulinIV QD | 8 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C) | Yes |
|
|
Yu et al. 2002 [35] | WHO 1979 | CADPS 1997 | Unclear | |
| Xuezhikang 600 mg, therapy (as same as control) | Placebo + conventional therapy (aspirin, nitrate esters, CCB and et al.) | 8 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C) | Yes |
|
Zhang 2010
[36] | Reference [8] | CADPS 1997 | Unclear | | (58–80, 72.3 in average)
/(59–82, 73.1 in average) | Xuezhikang 600 mg, | Fluvastatin 40 mg QD | 4 weeks | Serum lipid level (TC, TG, LDL-C, HDL-C) | Yes |
|
Zhang 2011
[37] | Unclear | mmol/L
or LDL- mmol/L
complicated with high TG level | Unclear | 40/40 |
| Xuezhikang 300 mg TID | Atorvastatin 20 mg/d QD | 8 weeks | Serum lipid level (TC, TG, LDL-C), ADs | Yes |
|
Zhou et al.
2003 [38] | Unclear | mmol/L and (or) LDL- mmol/L or complicate with >1.92 mmol/L | ACS | | | Xuezhikang 600 mg | Conventional therapy (nitrate esters, β adrenergic blocking agent, CCB, anticoagulation drugs, thrombolytic drug, PTCA and et al.) | 8 weeks | Serum lipid level (TC, TG, LDL-C) | Yes |
|
